Oncolys BioPharma Inc.

4588

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-07FY2026 Q2

Revenue

5100M JPY

YoY +1662.4%

Operating Income

-7.7100M JPY

YoY +39.4%

Net Income

-15.1100M JPY

YoY +32.8%

EPS

-26.0JPY

YoY +50.7%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

9.8億円

2.2億円

-5.4億円

-13億円

-20.6億円

Rev: 6.4億円Op: -14.5億円NI: -16.2億円

Rev: 9.8億円Op: -12億円NI: -11.5億円

Rev: 63百万円Op: -19.3億円NI: -19.4億円

Rev: 31.4百万円Op: -16.8億円NI: -16.8億円

Rev: 28.5百万円Op: -20.2億円NI: -20.6億円

2021/FY2022/FY2023/FY2024/FY2025/FY

Full-Year Progress

FY2026 Q2

Net Income-

Revenue Progress500M

Revenue Forecast-

Net Income Progress-

Net Income Forecast-

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan